PEPTIDE TELEHEALTH & PRESCRIBING COMPLIANCE
Keep your peptide clinic clinically sound and compliant
HCPA helps peptide telehealth clinics strengthen prescribing governance, patient records, practitioner oversight, advertising and the systems supporting safe care.
Peptide compliance depends on the product, prescribing pathway and clinical circumstances of each patient. Some peptide-based medicines are approved in Australia, while many products promoted online remain unapproved therapeutic goods.
When peptide clinic compliance needs immediate action
A regulatory concern may begin with a patient complaint, prescribing review, advertising issue or questions about an unapproved product. The priority is to identify exactly what is affected and whether any patient care needs immediate attention.
Issues involving prescribing, patient safety or prescription medicines can escalate quickly. Deal with the immediate clinical risk first, then preserve the records needed to understand what happened.
Prescribing concerns
Questions may arise where the patient assessment, clinical reasoning or evidence supporting the treatment is unclear.
This requires particular care for unapproved peptides because the TGA has not assessed the product for safety, quality or effectiveness.
Practitioner governance gaps
Practitioners need current registration, appropriate scope and clearly defined clinical responsibilities.
Clinic systems should support independent practitioner judgement rather than allowing commercial processes to determine what is prescribed.
Website and advertising issues
Peptide telehealth websites can create compliance problems when they promote particular prescription medicines, peptide products or expected treatment outcomes.
The TGA’s 2026 prescription medicine advertising guidance specifically warns that telehealth services can unlawfully advertise prescription medicines where the service is presented as a way to obtain them.
Patient records and privacy concerns
Incomplete records or poorly managed patient information can make it difficult to demonstrate what assessment occurred, why treatment was chosen and how follow-up was managed.
These gaps become particularly important when a complaint, audit request or investigation occurs.
Key peptide telehealth compliance requirements
A compliant peptide clinic needs its clinical model, product pathway and telehealth systems to work together.
Verify the peptide pathway and supporting evidence
Start by establishing whether the medicine is included in the ARTG or is an unapproved therapeutic good.
For unapproved peptides, the TGA advises practitioners to consider approved treatment options, assess risks and potential benefits, obtain informed consent and rely on human evidence relevant to the specific peptide, dosage form, route of administration and indication. See the TGA’s peptide guidance for health practitioners.
Use an appropriate telehealth assessment
Records should make the treatment decision understandable to another clinician or regulator reviewing it later.
Depending on the consultation, this may include the assessment, clinical reasoning, treatment alternatives, evidence considered, informed consent, prescribing decision, monitoring and follow-up.
Keep practitioner governance current
Registration, scope, insurance and prescribing responsibilities should be monitored after launch, not simply checked during onboarding.
Clinical decisions must remain with the treating practitioner and be based on the individual patient’s needs.
Keep advertising separate from prescribing decisions
Public marketing should promote the healthcare service without turning the website into a catalogue or pathway to specific prescription medicines.
Ahpra’s advertising guidelines for regulated health services also prohibit clinical testimonials and advertising that creates unreasonable expectations of beneficial treatment.
Strong peptide clinic compliance means the practitioner can explain why treatment was appropriate, while the clinic can demonstrate that its systems supported rather than influenced that clinical decision.
Peptide prescribing reviews and investigation readiness
There is no fixed annual audit cycle specifically for peptide telehealth clinics.
That does not mean clinics should wait for regulatory attention before reviewing compliance. Patient complaints, advertising concerns, prescribing issues or practitioner-governance weaknesses can all expose problems. This reflects the practical issues identified in HCPA’s peptide compliance work.
A prescribing review or professional investigation may look beyond one treatment and test whether the clinic’s broader systems support compliant practice.
A focused internal review may examine:
practitioner registration and scope
patient assessment and consultation records
clinical reasoning and treatment evidence
informed consent
SAS or Authorised Prescriber documentation where relevant
prescribing, monitoring and follow-up
website and advertising material
patient-data and governance controls
In 2026, the TGA has increased its focus on unapproved peptide products and has warned businesses about unlawful advertising, importation, manufacture and supply.
HCPA can review clinic systems and supporting evidence, identify gaps and help prepare an organised response where concerns arise.
What to do after a peptide prescribing audit or Ahpra investigation
Identify the issue
Confirm which practitioner, patient, prescription, advertisement or clinic process has been questioned.
Pause the affected activity where needed
Where continuing an activity could increase clinical or regulatory risk, address that issue first while maintaining appropriate patient care.
Preserve and review the evidence
Gather the relevant clinical records, prescribing evidence, practitioner documentation, website material and system records without retrospectively altering them.
Address the underlying gap
Identify the root cause, strengthen the relevant workflow or governance control and document the corrective action taken.
Why choose HCPA for peptide clinic compliance?
Peptide telehealth sits at the intersection of healthcare regulation, therapeutic goods requirements and a rapidly changing online market.
HCPA reviews these areas together rather than treating prescribing, practitioner governance, patient records and advertising as separate compliance exercises.
businesses supported
industry consultants
billion in client revenue
HCPA’s peptide compliance work can include reviewing the clinic from the patient’s perspective, checking website content, practitioner arrangements, clinical workflows and the systems supporting ongoing care.
Frequently asked questions about peptide telehealth compliance
What evidence should support the telehealth prescribing of approved or unapproved peptide products?
The record should show why the treatment was clinically appropriate for that patient.
For an unapproved peptide, the TGA expects practitioners to consider approved options, assess risks and potential benefits, obtain informed consent and use relevant human evidence for the specific peptide, dosage form, route and indication.
How should a peptide clinic respond to a prescribing audit or Ahpra investigation?
Start with the exact concern rather than rewriting every clinic policy.
Preserve the relevant evidence, identify any affected patients or practitioners, deal with immediate patient-care issues and then address the underlying clinical or governance gap.
Are peptide telehealth clinics subject to routine annual audits?
There is no specific annual regulatory audit cycle simply because a clinic offers peptide telehealth services.
However, complaints, advertising concerns, prescribing practices or other compliance issues can trigger regulatory scrutiny. Regular internal reviews can help identify gaps before they become a formal issue.
Can an unapproved peptide legally be prescribed?
Potentially, but it cannot simply be treated like an ARTG-approved medicine.
Certain unapproved therapeutic goods may be accessed through established pathways such as the Special Access Scheme or Authorised Prescriber Scheme where the relevant requirements are met. See the TGA’s unapproved therapeutic goods access pathways. Peptides in general are not illegal and they are still regulated by TGA and are safe to consume
Does “research use only” mean a peptide falls outside TGA regulation?
Not necessarily.
How a product is labelled does not by itself remove therapeutic-goods obligations where it is being promoted, supplied or used for therapeutic purposes.
Can a peptide clinic use before-and-after photos?
No.
Images may create compliance problems if they imply a guaranteed or typical result, create an unreasonable expectation of benefit or are accompanied by prohibited clinical testimonials. Ahpra specifically warns that before-and-after imagery can be misleading depending on the overall impression it creates.
What should a clinic review when onboarding a peptide prescriber?
Check current registration, insurance, scope of practice and understanding of the clinic’s telehealth and prescribing procedures.
The clinic should also establish how clinical decisions are documented, how unapproved products are accessed where relevant and how patients are escalated when telehealth or the proposed treatment is not appropriate.
Can the TGA take enforcement action over unapproved peptides?
Yes.
The TGA has stated that unlawful activity involving unapproved peptide products can lead to warning letters, infringement notices, seizures, civil penalties and, in serious cases, criminal prosecution.
Related peptide resources
Starting a peptide telehealth clinic
Planning to establish an Australia-wide telehealth service?
Grow your peptide clinic
Ready to attract more patients and strengthen clinic performance?
